Abituzumab in SSc-ILD

ClinicalTrials.gov ID: NCT02745145

Public ClinicalTrials.gov record NCT02745145. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the treatment of participants with SSc-ILD who already receive constant doses of mycophenolate.

Study identification

NCT ID: NCT02745145
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Enrollment: 24 participants

Conditions and interventions

Conditions

Systemic Sclerosis-associated Interstitial Lung Disease

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2016 (Actual)
Primary completion: May 30, 2018 (Actual)
Completion: May 30, 2018 (Actual)
Last update posted: Jun 18, 2019

2016 – 2018

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 15

Facility	City	State	ZIP	Site status
Research site 1	Los Angeles	California	90045	—
Research site	Los Angeles	California	90095-1690	—
Research site	Farmington	Connecticut	06030	—
Research site	Washington D.C.	District of Columbia	20007	—
Research site	Orlando	Florida	32803	—
Research site	Weston	Florida	33331	—
Research site	Chicago	Illinois	60611	—
Research site 1	Boston	Massachusetts	02114	—
Research site 2	Boston	Massachusetts	02118	—
Research site	Ann Arbor	Michigan	48109-5360	—
Research site	New Brunswick	New Jersey	08901	—
Research site	Great Neck	New York	11021	—
Research site 1	New York	New York	10021	—
Research site 2	New York	New York	10032	—
Research site	Portland	Oregon	97239	—
Research site	Nashville	Tennessee	37232	—
Research site	Dallas	Texas	75246	—
Research site	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02745145, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 18, 2019 · Synced Oct 26, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02745145 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →